Evidence map›Paper›PMID 24887129›Full record

ArticlePloS one2014

Chronic macrophage migration inhibitory factor exposure induces mesenchymal epithelial transition and promotes gastric and colon cancers.

Katherine T Morris, Robert A Nofchissey, Irina V Pinchuk, Ellen J Beswick

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Prognostic value of several biomarkers for the patients with malignant pleural mesothelioma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015
    Review
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Katherine T MorrisDepartment of Surgery, University of New Mexico, Albuquerque, New Mexico, United States of America.
Robert A NofchisseyDepartment of Molecular Genetics and Microbiology, University of New Mexico, Albuquerque, New Mexico, United States of America.
Irina V PinchukDepartment of Internal Medicine, Division of Gastroenterology and Hepatology, University of Texas Medical Branch, Galveston, Texas, United States of America.
Ellen J BeswickDepartment of Molecular Genetics and Microbiology, University of New Mexico, Albuquerque, New Mexico, United States of America.
University of New Mexico · USThe University of Texas Medical Branch at Galveston · US

Funding

WOMEN'S CANCERS RESEARCH PROGRAMP30CA118100 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Yolanda Sanchez · 2005 to 2026
$57.1M
UNM HSC Clinical and Translational Science CenterUL1TR001449 · NCATS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI CAMPEN, MATTHEW J, PANDHI, NANCY · 2015 to 2024
$36.9M
UNIVERSITY OF NEW MEXICO CLINICAL AND TRANSLATIONAL SCIENCE CENTERUL1RR031977 · NCRR · UNIVERSITY OF NEW MEXICO · PI LARSON, RICHARD S · 2010 to 2011
$8.8M
University of New Mexico Clinical and Translational Science CenterKL2TR000089 · NCATS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI LARSON, RICHARD S · 2012 to 2014
$909k
UTMB Clinical and Translational Science AwardKL2TR000072 · NCATS · UNIVERSITY OF TEXAS MED BR GALVESTON · PI BRASIER, ALLAN R. · 2012 to 2014
$422k
Potential Role of H. Pylori-induced MIF in Gastric CancerK22AI068712 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI BESWICK, ELLEN J. · 2008 to 2009
$269k
NCATS NIH HHS KL2 TR000072NCATS NIH HHS KL2TR000072NCATS NIH HHS KL2 TR000089NCATS NIH HHS UL1 TR001449NCI NIH HHS P30 CA118100NCRR NIH HHS 1UL1RR031977-01NCRR NIH HHS UL1 RR031977NIAID NIH HHS K22 AI068712
6 · The paper itself

Abstract

Macrophage Migration Inhibitory Factor (MIF) is an inflammatory cytokine that is highly produced in gastrointestinal cancers. Since chronic inflammation is a risk factor for tumorigenesis in these cancers, in this study, the role of MIF in pro-tumorigenic events was examined. MIF and its receptor, CD74, were examined in gastric and colon tumors and found to be increased in most tumors with significantly higher expression in tumors from patients with lymph node metastasis. MIF was also found to be highly produced by cancer associated fibroblasts isolated from human tumors compared to fibroblasts from matched normal tissues from uninvolved areas. Fibroblast-produced MIF highly increased GI cancer cell proliferation, which was decreased upon neutralizing MIF or CD74. Chronic MIF treatment led to sustained proliferation and signaling events in non-transformed GI fibroblast cells, which was maintained upon removing MIF treatment for 8 weeks. Additionally, chronic treatment of normal GI cells expressing fibroblast markers for up to 16 weeks with MIF led to a drastic decrease of fibroblast markers with concurrent increase of epithelial markers. Transformation was examined by telomerase and focus forming assays. These results suggest the MIF promotes mesenchymal epithelial transition, cell transformation and tumorigenesis in GI cancers, and thus may be an important link between chronic inflammation and tumorigenesis.

Indexed as

Colonic NeoplasmsEpithelial-Mesenchymal TransitionHumansMacrophage Migration-Inhibitory FactorsReal-Time Polymerase Chain ReactionStomach NeoplasmsMacrophage Migration-Inhibitory Factors

Identifiers

PMID24887129
PMCPMC4041794
OpenAlexW2076939933

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.